@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 2/5 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages

✅BRCAm= 10-20% of TNBC!
✅PD-L1 CPS>10= PFS & OS benefit w/ IO in mTNBC
✅PARPi= PFS benefit
✅Biomarkers, side effects, pt pref key

📚We captured much of @dradityabardia @ariellemedford’s discussion: twitter.com/i/events/15548…
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 3/5 #TumorBoardTuesday
Thursday Case🎀

How do you choose IO vs PARPi in #TNBC w #BRCA mutation? Check out the summary and algorithm below!
Important to know there are more 2L options as well, including sacituzumab-gov & other ADCs. New trials evaluating IO+ PARPi–stay tuned!
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD @DFCI_BreastOnc @oreganruth @marina_sharifi @JaniceTNBCmets @OncBrothers @Myshastry @BRCAUmbrella 5/5 #TumorBoardTuesday
Thursday Case🎀

As always, we’re learning that new ways to apply molecular alterations & biomarkers to make better tx choices.

Thanks for joining us!
➡️Be sure to join us on 08/09/22 when @brian_rini brings us updates on adj tx in #RenalCellCancer😀

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Johnathan Ebben MD, PhD

Johnathan Ebben MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @JohnEbbenMDPhD

Jul 22
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 1/8 #TumorBoardTuesday

🔬🧬Discussion on 1L treatment for BRCA+ #MBC led by @PTarantinoMD @CaterinaSpo #BreastCancer

➡️Here’s the week's Thursday Case 🎀

👉Don’t forget your🆓 #CME credit by answering 1 quick❓
CME🔗: integrityce.com/tbt
CME eval🔗: integrityce.com/tbteval
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 2/8 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages for germline #BRCAm & 2L tx in #BreastCancer
✅BRCAm fairly common - 10-20% of #TNBC
✅PARPi approved in met, BRCAm dz
✅Fast responses, with ORR > chemo

📚Much of @PTarantinoMD @CaterinaSpo’s chat👇🏽
twitter.com/i/events/15487…
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 2.33/8 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages (continued):

✅Toxicities for 🤢, myelosuppression- managed w ⬇️ reduction, tx holiday
‼️(remember 3-5% risk of MDS/AML)‼️
Read 15 tweets
Jul 15
@TumorBoardTues @CharuAggarwalMD @ADesaiMD @Latinamd @PTarantinoMD @LealTiciana @NarjustFlorezMD 1/8 #TumorBoardTuesday
🔬🧬@CharuAggrawalMD @ADesaiMD taught us about EGFR mutations in #LungCancer–specifically, new 2L strategies for EGFRexon20m.

➡️Here's this week's Thursday Case🎀
Pick up your 🆓#CME
ALL CME 🔗: integrityce.com/tbt
CME eval🔗: integrityce.com/tbteval
@TumorBoardTues @CharuAggarwalMD @ADesaiMD @Latinamd @PTarantinoMD @LealTiciana @NarjustFlorezMD 2/8 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
We discussed #EGFR mutations in #LungCancer
✅Not all EGFR mutations are the same!
✅Osimertinib=tx for most activating EGFR mutations
✅…but exon20insmut more resistant to TKIs
✅Amivantamab, mobocertinib= 2L strategies
@TumorBoardTues @CharuAggarwalMD @ADesaiMD @Latinamd @PTarantinoMD @LealTiciana @NarjustFlorezMD 2.5 / 8 #TumorBoardTuesday

📚We captured as much of @CharuAggrawalMD @ADesaiMD’s discussion as we could in this moment: twitter.com/i/events/15463…

CRITICAL point: if you don’t look, you won’t know! RNA based NGS recommended for 🫁cancer cases to identify actionable mut
Read 17 tweets
Jul 1
@TumorBoardTues @Dr_RShatsky @PTarantinoMD @ErikaHamilton9 @UCSDCancer @KariWisinski_MD @marina_sharifi @JPoteralaMD @LaurenBzak @benjiwal @drteplinsky @MarkRobsonMD 2/11 #TumorBoardTuesday
Thurs Case🎀
Take🏠:
#TNBC &neoadjuvant tx
✅KEYNOTE-522= new standard of care
– Pembro+chemo in neoadj= BEST pCR so far
– Caveat: only for T2+ TNBC
✅Adding pembro may have ⬆️benefit in RCB II
📚We captured much of chat:
p1: twitter.com/i/events/15423…
@TumorBoardTues @Dr_RShatsky @PTarantinoMD @ErikaHamilton9 @UCSDCancer @KariWisinski_MD @marina_sharifi @JPoteralaMD @LaurenBzak @benjiwal @drteplinsky @MarkRobsonMD 3/11 #TumorBoardTuesday
Thurs Case🎀
Take🏠msgs (cont’d):
✅IO NOT shown to add benefit in metastatic dz
– Atezolizumab approval in mTNBC withdrawn
✅Standard of care – multi-d team
✅No current evidence to hold IO pre-op
P2: twitter.com/i/events/15425…
@TumorBoardTues @Dr_RShatsky @PTarantinoMD @ErikaHamilton9 @UCSDCancer @KariWisinski_MD @marina_sharifi @JPoteralaMD @LaurenBzak @benjiwal @drteplinsky @MarkRobsonMD 4/11 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages (cont’d):
✅THINK about side FX, including fertility
— Ovarian suppression may preserve fertility while undergoing neoadj tx
✅Patient voice is MOST important- pts define “acceptable tox,” not 🩺
Read 16 tweets
Jun 17
1/8 IT’S #TumorBoardTuesday CASE WRAP UP TIME!

🫁@NarjustFlorezMD @ShrutiPatelMD taught us about EGFR mutated #NSCLC & adjuvant therapy–rapidly changing field. Summary below!

👉Don’t forget to grab🆓#CME (AMA/MOC) w 2 quick❓ CME eval & rationale🔗: integrityce.com/tbteval Image
2/8 #TumorBoardTuesday
Thurs Case🎀

Take🏠-pt 1
We discussed #NSCLC & EGFRm
✅EGFR mutations:
🔹Female>Male;
🔹Never smoker >> smoker
✅NEED‼️NGS data‼️BEFORE systemic tx. Order panel of common EGFR muts if limited time.

We captured much of chat:
P1: twitter.com/i/events/15369…
2.33 #TumorBoardTuesday
Thurs Case🎀
Take🏠msgs:
✅Osimertinib= EGFRi w demonstrated DFS⬆️in adj setting; waiting on OS data
✅Osi best TKI (Drake says so), diff strategies for diff mutations (i.e. ex20)
✅THINK about side FX, including fertility

P2: twitter.com/i/events/15372…
Read 15 tweets
May 27
@TumorBoardTues @MPishvaian @SushmaJonna @Latinamd @GDutcherMD @Empoweringpts9 @ADesaiMD @JackWestMD @DrSteveMartin @esinghimd @GO2Foundation 1/13 #TumorBoardTuesday #LCSM
➡️Here’s this week's Thursday Case🎀!

🧬@Latinamd @GDutcherMD took us through METex14 skipping in older pts with 🫁#NSCLC.

👉Get 🆓#CME credit with quick❓

CME eval 🔗: integrityce.com/tbteval

@SylvesterCancer
@TumorBoardTues @MPishvaian @SushmaJonna @Latinamd @GDutcherMD @Empoweringpts9 @ADesaiMD @JackWestMD @DrSteveMartin @esinghimd @GO2Foundation @SylvesterCancer 2/13 #TumorBoardTuesday
Thurs Case🎀

Take🏠points:

#LungCancer= molecular disease

✅IDEAL=wait for NGS before tx
✅Send tissue NGS & ct🧬
✅MET mut= RTK driver- rare!
🔷MET exon 14 skipping best detected w RNAseq
🔷Capmatinib/tepotinib= FDA👍🏽
✅METi side effects: 🤨EDEMA
@TumorBoardTues @MPishvaian @SushmaJonna @Latinamd @GDutcherMD @Empoweringpts9 @ADesaiMD @JackWestMD @DrSteveMartin @esinghimd @GO2Foundation @SylvesterCancer 3/13 #TumorBoardTuesday
Thurs Case🎀

Take🏠points (cont’d):

✅🎯tx preferred in 1L >> IO
🗝️ IO first 👉🏽TKI (osi) 👉🏽⬆️irAE
✅Older pts may need dose adjustment of TKI d/t tox
✅MET bispecifics (amivantamab) & ADCs coming!
Read 20 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(